Late-Breaking Science | Scientific Sessions

24 Aha Tb 0017298 (1)

LBS 01: Celebrating a century of cardiovascular science

Intensive blood pressure control, tirzepatide and novel gene editing therapy.

241116 American Heart Association Keynote 0080

LBS 08: Advances in lipid therapeutics

LBS 07: New approaches to managing AFib

LBS 06: Medical therapy for heart failure

LBS 05: Innovation in prevention

French Quarter balcony shot

Save the date for #AHA25 in New Orleans

Stage shot

LBS 04: Coronary and valvular heart disease

Liberal or restrictive oxygenation, GLP-1 agonist therapy, edoxaban and spironolactone.

Screening for Kidney Disease to Reduce CVD Risk

Screening for Kidney Disease to Reduce CVD Risk

uACR and eGFR testing are the first step.

Stage shot

LBS 03: Harnessing AI for better heart health

Improving guideline-directed medical therapy, comparing wearable versus implanted sensors, boosting echocardiogram performance and automating echocardiographic interpretation.

audience shot

LBS 02: Redefining arrhythmia treatment

Catheter ablation, OPTION and Brain-AF.

audience shot

Clinical Guideline Sessions

Get up to speed on all of the updates in guidelines.

audience shot

Late-Breaking Science for Sunday

Two presentations feature results from intervention and prevention studies.

audience shot

Featured Science for Saturday

Check out these featured studies.

audience shot

Don't miss today's Main Events

Six powerful Main Events to kick off your Scientific Sessions 2024.

audience shot

Cutting-edge science highlights #AHA24

#AHA24 has slated presentation of 29 Late-Breaking Science results and 29 Featured Science studies during the meeting.

late breaking science audience and presentation

#AHA24 Late-Breaking and Featured Science announced

See the impressive lineup of science planned for presentation at Scientific Sessions 2024.

Audience shot

Late-breaking science| Achieving equity in prevention

audience shot

Novel mechanisms for lipid-lowering therapy

LBS 08 panelists

Late-breaking science: AI at the bedside

Lbs05 Panel Web

Shocking decisions in AFib care

Lbs04 Panel2 Web

Drugs, diet and delivery can optimize hypertension outcomes

audience shot

Heart failure late-breaking science

A. Michael Lincoff, MD

Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes

From left: Christopher Rajkumar, MD, MRC, Jeffrey L. Carson, MD, MACP; Stefan James, MD.

Trials’ results suggest new approaches to reducing CVD risk and symptoms

AHA audience

Late-Breaking Science announced

audience

Early ablation bests medication in treatment naïve AFib patients

audience shot

First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension